ECM
CYTK icon

Element Capital Management’s Cytokinetics CYTK Stock Holding History

Element Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-31,475
Closed -$255K – 377
2019
Q1 		$255K Buy
+31,475
New +$231K 0.01% 647

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Element Capital Management's CYTK Position: Q2 2019 in Review

Element Capital Management sold out of Cytokinetics (CYTK) in Q2 2019, closing a stake of 31,475 shares — an estimated $255K sold.

Element Capital Management first reported a position in CYTK in Q1 2019 and held it in 1 quarter. The position peaked at $255K in Q1 2019. 134 funds tracked by Wall St. Rank hold CYTK as of Q2 2019.

  • Element Capital Management reported no remaining Cytokinetics position as of Q2 2019 after selling out during the quarter.
  • Element Capital Management sold 31,475 Cytokinetics shares in Q2 2019, an estimated $255K.
  • Element Capital Management first reported a position in Cytokinetics in Q1 2019 and held it in 1 quarter.
  • Element Capital Management's Cytokinetics position peaked at $255K in Q1 2019.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.